Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Marky1on Mar 16, 2020 5:35pm

195 Views

Post# 30814594

Final Farewell

I'd like to say a final ta ta...I'm only going to resurface when ATE is over 2$...

To all the longs, stay safe and stay well....and...no...Mugsy I will not be reading any comments from here on.

i firmly believe in the ATB346 molecule and it's bright future in the days ahead..My biochemistry knowledge, knowing the great benefits of H2S on the body gives me great confidence in ANTIBE s futur..Some Large Pharma ( Pfizer hopefully ) is going to reap great fortunes owning this molecule

Take care, fellow shareholders

Jean Marc

i